Results 31 to 40 of about 4,836 (234)

Simultaneous administration of imipenem/cilastatin/relebactam with selected intravenous antimicrobials, a stewardship approach.

PLoS ONE, 2020
Imipenem/cilastatin/relebactam is a β-lactam/β-lactamase inhibitor that has been recently FDA approved for complicated intra-abdominal and urinary tract infections under the brand name Recarbrio®.
Islam M Ghazi, Wasim S El Nekidy, Regan Asay, Paul Fimognari, Anthony Knarr, Mina Awad   +5 more
doaj   +4 more sources

Klebsiella pneumoniae Susceptibility to Carbapenem/Relebactam Combinations: Influence of Inoculum Density and Carbapenem-to-Inhibitor Concentration Ratio

Biomedicines, 2022
The inoculum effect (IE) is a well-known phenomenon with beta-lactams. At the same time, the IE has not been extensively studied with carbapenem/carbapenemase inhibitor combinations.
Maria V. Golikova, Kamilla N. Alieva, Alla V. Filimonova, Vladimir A. Ageevets, Ofeliia S. Sulian, Alisa A. Avdeeva, Sergey V. Sidorenko, Stephen H. Zinner   +7 more
doaj   +1 more source

Combinación de antibióticos carbapenémicos con relebactam sobre enterobacterias productoras de carbapenemasas

Correo Científico Médico
Las enterobacterias productoras de carbapenemasas se han diseminado por todo el mundo y causan infecciones de alta mortalidad y morbilidad. Los antibióticos carbapenémicos se utilizan como último recurso frente a las infecciones graves producidas por ...
Washington Paúl Culqui Molina, Martha Elizabeth Loor Flores, Mónica Viviana Moscoso Silva   +2 more
doaj   +1 more source

Pharmacokinetics, Safety, and Tolerability of Imipenem/Cilastatin/Relebactam in Children with Confirmed or Suspected Gram-Negative Bacterial Infections: A Phase 1b, Open-Label, Single-Dose Clinical Trial [PDF]

, 2023
Imipenem/cilastatin/relebactam is approved for the treatment of serious gram-negative bacterial infections in adults. This study assessed the pharmacokinetics (PK), safety, and tolerability of a single dose of imipenem/cilastatin/relebactam (with a fixed
Bradley, John S, Chen, Luke F, Kelly, Matthew S., Makieieva, Nataliia, Maniar, Alok, Paschke, Amanda, Patel, Munjal, Roilides, Emmanuel, Tøndel, Camilla, Vaddady, Pavan, Zhang, Ying   +10 more
core   +1 more source

New evidence in severe pneumonia: imipenem/ cilastatin/relebactam

Revista Española de Quimioterapia, 2022
Imipenem combined with beta-lactamase inhibitor relebactam (IMI/REL) has an extensive bactericidal activity against Gram-negative pathogens producing class A or class C beta-lactamases, not active against class B and class D. The phase 3 clinical trial (RESTORE-IMI-2), double-blind, randomized, evaluated IMI/REL vs.
Girón, R M, Ibáñez, A, Gómez-Punter, R M, Alarcón, T   +3 more
openaire   +4 more sources

Activity of imipenem/relebactam against Enterobacterales and Pseudomonas aeruginosa in Spain. SMART 2016-2020 [PDF]

, 2023
Objectives. To determine susceptibility to the novel β-lactam/β-lactamase inhibitor combination imipenem/relebactam in clinical isolates recovered from intra-abdominal (IAI), urinary (UTI), respiratory (RTI) and bloodstream (BSI) infections in the SMART (
Calvo, Jorge, Cantón, Rafael, Castillo, Francisco Javier, Cercenado, Emilia, Díaz-Regañón, Jazmín, Fariñas, María Carmen, Fernández-Billón, María, Figueroa Cerón, Ruth Esther, García-Fernández, Sergio, González Romo, Fernando, Gálvez-Benítez, Lydia, Gómez, María, Hernández-Cabezas, Alicia, Suárez-Barrenechea, Ana Isabel, Tubau, Fe   +14 more
core   +1 more source

In Vitro Susceptibility of Aztreonam-Vaborbactam, Aztreonam-Relebactam and Aztreonam-Avibactam Associations against Metallo-β-Lactamase-Producing Gram-Negative Bacteria

Antibiotics, 2023
Background: Despite the availability of new options (ceftazidime-avibactam, imipenem-relebactam, meropenem-vaborbactam and cefiderocol), it is still very difficult to treat infections caused by metallo-β-lactamase (MBLs)-producers resistant to aztreonam.
Cécile Emeraud, Sandrine Bernabeu, Laurent Dortet   +2 more
doaj   +1 more source

In vitro activity of imipenem/relebactam against Enterobacteriaceae and Pseudomonas aeruginosa isolated from intraabdominal and urinary tract infection samples: SMART Surveillance United States 2015–2017

Journal of Global Antimicrobial Resistance, 2020
Objectives: Antimicrobial resistance, including multidrug-resistance (MDR), is increasing, especially among Gram-negative bacilli. New agents are needed to treat infections caused by these pathogens.
James A. Karlowsky, Sibylle H. Lob, Krystyna M. Kazmierczak, Katherine Young, Mary R. Motyl, Daniel F. Sahm   +5 more
doaj   +1 more source

Relebactam restores susceptibility of resistant Pseudomonas aeruginosa and Enterobacterales and enhances imipenem activity against chromosomal AmpC-producing species: analysis of global SMART 2018–2020

BMC Microbiology, 2023
Background Carbapenem-resistant bacteria are an increasing problem in clinical practice; thus, it is important to identify β-lactamase inhibitors (e.g., relebactam) that can restore carbapenem susceptibility.
David W. Hilbert, C. Andrew DeRyke, Mary Motyl, Meredith Hackel, Katherine Young   +4 more
doaj   +1 more source

Lung penetration, bronchopulmonary pharmacokinetic/pharmacodynamic profile and safety of 3 g of ceftolozane/tazobactam administered to ventilated, critically ill patients with pneumonia [PDF]

, 2020
Objectives: Ceftolozane/tazobactam is approved for hospital-acquired/ventilator-associated bacterial pneumonia at double the dose (i.e. 2 g/1 g) recommended for other indications.
Adedoyin, Adedayo, Caro, Luzelena, De Waele, Jan, Gadzicki, Elaine, Kuti, Joseph L, Larson, Kajal B, Nicolau, David P, Rhee, Elizabeth G, Yu, Brian, Zeng, Zhen   +9 more
core   +1 more source